Bayer’s Roundup pesticide is linked with cancer. Its fight to dodge accountability threatens to leave sick people holding the ...

This episode of Pharma Pulse covers Bayer’s $2.3 billion cost-cutting overhaul, promising Phase III results for Eli Lilly’s oral GLP-1 therapy orforglipron, and a pivotal court decision clearing the ...

Facing another 61,000 unresolved lawsuits claiming its weedkiller causes cancer, Bayer added $1.2 billion to its glyphosate ...

Crop science giant Bayer says it has settled 17,000 glyphosate cases so far and hopes for a supreme court ruling next year.

Bayer has recently settled thousands of cases over claims the active ingredient in its Roundup weedkiller causes cancer, ...

Heading into the second half of their 2025 financial year, Bayer leaders echo positive comments surrounding the company’s ...

The German giant has already trimmed more than 10,000 employees since initiating a massive restructuring initiative in July ...

Bayer AG (BAYRY) reported second-quarter 2025 core earnings of 35 cents per American Depositary Receipt (ADR), which ...

We affirm our objective to significantly contain the litigation risk by the end of 2026,” CEO Bill Anderson noted said. As part of its ...

Bayer, which is burdened by U.S. lawsuits claiming that its Roundup weedkiller causes cancer, has said it is holding off on breaking up the diversified group amid calls by some investors to sell the ...

Bayer Aktiengesellschaft boosted 2025 sales outlook with pharma growth and lower litigation costs. Click for why BAYRY is an ...

The additional financial provisions support Bayer’s stated goal to get glyphosate litigation and liabilities contained by ...